PubRank

Premlata Shankar

Author PubWeight™ 64.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003 7.37
2 Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005 6.40
3 siRNA-directed inhibition of HIV-1 infection. Nat Med 2002 6.36
4 miRNA profiling of naïve, effector and memory CD8 T cells. PLoS One 2007 5.43
5 Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007 5.21
6 T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008 4.32
7 Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003 2.26
8 Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 2002 1.94
9 Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 2009 1.65
10 RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2009 1.55
11 A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med 2006 1.55
12 Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 2005 1.54
13 Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 2010 1.28
14 Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med 2003 1.10
15 The functional CD8 T cell response to HIV becomes type-specific in progressive disease. J Clin Invest 2002 1.09
16 Newer gene editing technologies toward HIV gene therapy. Viruses 2013 1.07
17 Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J Virol 2009 1.06
18 Interfering antiviral immunity: application, subversion, hope? Trends Immunol 2006 1.03
19 NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site. PLoS Pathog 2006 0.99
20 Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model. Proc Natl Acad Sci U S A 2012 0.94
21 Avoiding the kiss of death: how HIV and other chronic viruses survive. Curr Opin Immunol 2002 0.93
22 Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis. PLoS One 2011 0.89
23 Improved siRNA/shRNA functionality by mismatched duplex. PLoS One 2011 0.89
24 Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA. Mol Ther 2010 0.87
25 RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther 2010 0.87
26 Humanized mice for studying human leukocyte integrins in vivo. Methods Mol Biol 2012 0.85
27 Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol Biol 2011 0.85
28 Long-term engraftment of human natural T regulatory cells in NOD/SCID IL2rγc(null) mice by expression of human IL-2. PLoS One 2012 0.84
29 Single amino acid change in gp41 region of HIV-1 alters bystander apoptosis and CD4 decline in humanized mice. Virol J 2011 0.82
30 Effective suppression of HIV-1 by artificial bispecific miRNA targeting conserved sequences with tolerance for wobble base-pairing. Biochem Biophys Res Commun 2008 0.81
31 Cross-clade CD8 T-cell responses to HIV(IIIB) and Chinese B' and C/B' viruses in North American and Chinese HIV-seropositive donors. J Acquir Immune Defic Syndr 2004 0.80
32 Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy. Virology 2011 0.78
33 Targeting DNA vaccines to myeloid cells using a small peptide. Eur J Immunol 2014 0.76